We are live on ! Find out more
IGC icon

IGC Pharma
IGC

7 hedge funds and large institutions have $68K invested in IGC Pharma in 2016 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 2 increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

134% more capital invested

Capital invested by funds: $29K → $68K (+$39K)

40% more funds holding

Funds holding: 5 → 7 (+2)

Holders
7
Holders Change
+2
Holders Change %
+40%
% of All Funds
0.17%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
2
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Creative Planning
Creative Planning
Kansas
+$21.5K
2
Citadel Advisors
Citadel Advisors
Florida
+$16.4K
3
VKH
Virtu KCG Holdings
New York
+$14.5K
4
UBS Group
UBS Group
Switzerland
+$9.94K

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
Creative Planning
1
Creative Planning
Kansas
$18K +$21.5K +61,899 +1,965%
PAM
2
Panagora Asset Management
Massachusetts
$14K – – –
Citadel Advisors
3
Citadel Advisors
Florida
$13K +$16.4K +47,210 New
VKH
4
Virtu KCG Holdings
New York
$12K +$14.5K +41,841 New
UBS Group
5
UBS Group
Switzerland
$10K +$9.94K +28,647 +507%
GI
6
Gradient Investments
Minnesota
$1K – – –

IGC Hedge Fund Activity: Q4 2016 in Review

7 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in IGC Pharma (IGC) for Q4 2016, worth a combined $68K — up 134% from $29K a quarter earlier.

Buyers outnumbered sellers: 2 funds opened new IGC positions and 0 closed out — a net gain of 2 holders — while 2 added to existing stakes and 0 trimmed.

The largest buyer was Creative Planning, adding an estimated $21.5K.

  • 7 institutional investors held IGC Pharma (IGC) as of Q4 2016, up from 5 in Q3 2016.
  • Funds reported $68K of IGC Pharma stock for Q4 2016, up 134% quarter-over-quarter.
  • 2 funds opened new IGC Pharma positions in Q4 2016 and 0 closed out, a net change of +2 holders.
  • The largest IGC Pharma buyer in Q4 2016 was Creative Planning, an estimated $21.5K added.

Based on aggregated 13F filings for Q4 2016.